Agios Pharmaceuticals | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 9.71B 96M 2025-06
Agios Pharmaceuticals USD 139.51M 24.16M 2025-06
Alnylam Pharmaceuticals USD 789.89M 213.78M 2025-06
Amgen USD 6.52B 337M 2025-06
Arrowhead Research USD 193.32M 31.81M 2025-06
Astellas Pharma JPY 413.25B 17.48B 2025-06
AstraZeneca USD 10.95B 1.04B 2025-06
Bayer EUR 10.73B 688M 2025-06
Biogen USD 1.79B 326.1M 2025-06
BioMarin Pharmaceutical USD 548.52M 27.27M 2025-06
Bristol-Myers Squibb USD 8.5B 265M 2025-06
Daiichi Sankyo JPY 377.89B 57.19B 2025-06
Eli Lilly USD 8.54B 1.22B 2025-06
Exelixis USD 354.68M 13.9M 2025-07
Gilead Sciences USD 4.35B 80M 2025-06
GlaxoSmithKline GBP 5.96B 663M 2025-06
Incyte USD 904.7M 56.97M 2025-06
Ionis Pharmaceuticals USD 312.21M 34.21M 2025-06
Merck USD 9.44B 217M 2025-06
Moderna USD 1.04B 113M 2025-06
Novartis USD 9.97B 1.02B 2025-06
Novartis USD 10.15B 579M 2024-12
Pfizer USD 11.62B 1.58B 2025-06
Regeneron Pharmaceuticals USD 2.6B 159.1M 2025-06
Roche Holding CHF 11.43B 1.48B 2024-12
Sarepta Therapeutics USD 495.51M 549.73M 2025-06
Vertex Pharmaceuticals USD 1.81B 71.4M 2025-06


Agios Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.